Tag: response

HOUSTON, TX, June 13, 2025 (GLOBE NEWSWIRE) -- Houston American Energy Corp. (NYSE American: HUSA) (“HUSA” or the “Company”) announced today that the Company had become aware of unusual trading activity in its common stock on the New York Stock Exchange American (the “NYSE”) on June 12 and June 13, 2025. The Company is issuing this press release pursuant to Section 401(d) of the NYSE Company Guide. The Company has made inquiries and has been unable to determine whether corrective actions are appropriate at this time. The Company is further announcing that there has been no material development in its business and affairs not previously disclosed or, to its knowledge, any other reason to account for the unusual market action.

New York City, NJ, June 13, 2025 (GLOBE NEWSWIRE) --

The cryptocurrency market is undergoing a new round of explosive changes—Bitcoin has broken through the $100,000 mark, the US has relaxed regulations, and Russia has fully legalised mining. These monumental shifts are reshaping the global financial landscape. In response, cloud mining is increasingly recognized as a pivotal pathway for ordinary investors seeking entry into the market, offering compelling advantages such as zero hardware investment and freedom from ongoing operation and maintenance costs. The following key trends and strategies will help you seize the unique opportunities presented by this evolving digital economy.

Radcred’s exclusive 2025 study reveals the safest, fastest-paying crypto casinos reshaping online gambling. See trends, data, and tips. 

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that dosing has commenced at the prestigious Weill Cornell Medicine Multiple Sclerosis Center in New York City, in its ongoing Phase 2 clinical trial evaluating intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). This fifth site complements existing sites at Yale University, Johns Hopkins University, Brigham and Women's Hospital, and the University of Massachusetts.